Background In adults with active lupus nephritis, the efficacy and safety of intravenous
belimumab as compared with placebo, when added to standard therapy (mycophenolate mofetil …

Objectives To identify factors that predict response to belimumab treatment in the phase 3
BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse …

We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis (BLISS-LN),
a Phase 3, multinational, double-blind, 104-week trial, in which 448 patients with …

Objectives This ongoing Phase-2, randomised, placebo-controlled, double-blind study
evaluated the efficacy, safety and pharmacokinetics of intravenous belimumab in childhood-onset …

Objective To investigate the long‐term safety and efficacy of intravenous ( IV ) belimumab plus
standard of care ( SOC ) therapy for systemic lupus erythematosus ( SLE ) in patients with …

Objective To evaluate the safety and efficacy of belimumab as adjunctive therapy to maintain
remission in antineutrophil cytoplasmic antibody ( ANCA )–associated vasculitis ( AAV ). …

Objective Enrollment of patients of Black African ancestry with systemic lupus erythematosus
(SLE) in phase II and phase III of the belimumab trials was not reflective of the racial …

Objective This extension study of the Phase III, randomized, placebo-controlled Belimumab
International SLE Study (BLISS)-52 and BLISS-76 studies allowed non-US patients with SLE …

Four hundred and eighty Chinese subjects with hepatitis B e antigen (HBeAg)–positive
chronic hepatitis B (CHB) were enrolled in a multicenter, double‐blind, randomized, placebo‐…

Objective. This observational study was a retrospective analysis of prospectively collected
Hopkins Lupus Cohort data to compare longterm renal survival in patients with lupus nephritis …